These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker
ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.
PacBio Enters Carrier Screening Market With PureTarget Expansion
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada ( KMDA Quick QuoteKMDA - ) and Illumina ( ILMN Quick QuoteILMN - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer ...
TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?
As precision oncology advances, Tempus and Illumina lead the way with innovation. Which stock shows stronger growth momentum now?
Here's Why Illumina ( ILMN ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD
TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
China's MGI Tech touts 10-minute genome reading with new sequencer
Shenzhen-based MGI Tech unveiled what it claims to be the world's fastest gene sequencer, an advance that promises to help accelerate breakthroughs in cancer genomics and rare disease research. The company said at a launch event on Tuesday that the DNBSEQ-T7+ can sequence 144 human genomes a day, ...
ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay
The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.
CRISPR Therapeutics ( CRSP ) Down 5.3% Since Last Earnings Report: Can It Rebound?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Scan, Play, Discover: Orca Scan Launches QR-Powered Retro Game
CAMBRIDGE, England, Sept. 2, 2025 /PRNewswire/ -- 'OrcaCam' showcases Cambridge's history of innovation and demonstrates how a simple QR code can instantly launch a cross-platform game on any device - with no download required.
Why Illumina ( ILMN ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Boston Scientific Stock Be in Your Portfolio Right Now?
BSX's global expansion and MedSurg growth boost Q2 momentum, though currency and macro headwinds weigh on the same.
Icahn Hedge Fund's Q2 Moves: Centuri Stake Soars, JetBlue Held, 2 Positions Exited - SandRidge Energy ( NYSE:SD ) , JetBlue Airways ( NASDAQ:JBLU ) , Centuri Holdings ( NYSE:CTRI ) , Intl Flavors & Fragrances ( NYSE:IFF )
Icahn boosts Centuri stake 158%, keeps JetBlue and utilities steady. Portfolio shifts favor infrastructure, utilities, and cash flow over cyclical or speculative bets. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
NICE Stock Stops Being Nice, Has A Bearish Breakdown - Illumina ( NASDAQ:ILMN ) , NICE ( NASDAQ:NICE )
NICE Ltd. NICE has entered Phase 9 of its 18-phase Adhishthana cycle on the monthly chart, and the technical picture has deteriorated. The stock appears to have broken its Adhishthana Cakra to the downside, a signal that often precedes a long stretch of consolidation and weakness.
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Cathie Wood's Thursday Bet: ARK Just Bought $31 Million Worth Of Falling Deere Stock, Also Loads Up On Block, Robinhood Shares - ARK Innovation ETF ( BATS:ARKK )
Ark Invest, led by Cathie Wood, made significant trades on Thursday - focusing on Deere & Co. DE, Block Inc. XYZ and Robinhood Markets Inc. HOOD. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started WiserAdvisorGet matched with a trusted, local financial advisor for ...
BioStem Technologies Appoints Brandon Poe as Chief Financial Officer - BioStem Technologies ( OTC:BSEM ) , Illumina ( NASDAQ:ILMN )
POMPANO BEACH, Fla., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- BioStem Technologies, Inc. ( "BioStem" or the "Company" ) BSEM, a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the ...
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada ( KMDA Quick QuoteKMDA - ) and Illumina ( ILMN Quick QuoteILMN - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Illumina Settles With DOJ, Veterans To End Whistleblower Lawsuit - Illumina ( NASDAQ:ILMN )
Illumina will pay $9.8 million, including $4.3 million in restitution, to settle false claims related to software vulnerabilities. Whistleblower will receive $1.9 million from the settlement under the False Claims Act. Get special access to three exclusive "Top 10 Stocks" power lists today, ...
Illumina ( ILMN ) Reliance on International Sales: What Investors Need to Know
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
What Does the Market Think About Illumina? - Illumina ( NASDAQ:ILMN )
Illumina's ILMN short percent of float has risen 12.85% since its last report. The company recently reported that it has 7.89 million shares sold short, which is 7.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.56 days to cover their ...
Illumina ( ILMN ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 31, 2025 at 8:30 p.m. ETChief Executive Officer - Jacob ThaysenContinue reading ...
Illumina ( ILMN ) Q2 EPS Jumps 9%
Illumina ( NASDAQ:ILMN ) , a global leader in DNA sequencing and genomics, released its second quarter results on July 31, 2025, for the fiscal 2025 period. The results were notable for beating analyst expectations on both non-GAAP EPS and GAAP revenue.
These Analysts Boost Their Forecasts On Illumina Following Upbeat Results - Illumina ( NASDAQ:ILMN )
Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday. The company posted quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.01 per share. The company reported quarterly sales of $1.059 billion which beat the analyst ...
Illumina: A 5.2 Rating Amid Challenges and Opportunities
Explore the exciting world of Illumina ( NASDAQ: ILMN ) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of Jul. 9, 2025.
Illumina ( ILMN ) Q2 Earnings and Revenues Surpass Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Gear Up for Illumina ( ILMN ) Q2 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
CRISPR Therapeutics AG ( CRSP ) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix ( CRMD ) Soars 5.1%: Is Further Upside Left in the Stock?
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Illumina ( ILMN ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cathie Wood Buys The Nvidia Dip Amid Panic Over Stargate Project: Ark Swoops Up $2 Million Worth Of Hot AI Stock - ARK Space Exploration & Innovation ETF ( BATS:ARKX ) , NVIDIA ( NASDAQ:NVDA )
On Tuesday, Cathie Wood's Ark Invest made a notable move by purchasing shares of NVIDIA Corp NVDA amid concerns surrounding a significant AI project.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Illumina Stock: What Went Wrong And Why It's Best To Stay Away - Illumina ( NASDAQ:ILMN )
Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?
HRMY vs. ILMN: Which Stock Is the Better Value Option?
Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?
BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.
Agenus ( AGEN ) Surges 19.3%: Is This an Indication of Further Gains?
Agenus (AGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's How Much a $1000 Investment in Agilent Technologies Made 10 Years Ago Would Be Worth Today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
iRhythm Technologies Announces Board Member Retirements and New Director Appointments
SAN FRANCISCO, July 07, 2025 ( GLOBE NEWSWIRE ) -- iRhythm Technologies, Inc. ( NASDAQ:IRTC ) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and ...
iRhythm Technologies Announces Board Member Retirements and New Director Appointments - Absci ( NASDAQ:ABSI ) , Alphatec Holdings ( NASDAQ:ATEC )
SAN FRANCISCO, July 07, 2025 ( GLOBE NEWSWIRE ) -- iRhythm Technologies, Inc. IRTC , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph ...
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
TEM is scaling fast. Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Laboratory Information Management System Market worth US$5.19 billion by 2030 with 12.5% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 27, 2025 ( GLOBE NEWSWIRE ) -- The global laboratory information management system market, valued at US$2.54 billion in 2024, stood at US$2.88 billion in 2025 and is projected to advance at a resilient CAGR of 12.5% from 2025 to 2030, culminating in a forecasted valuation ...
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
